查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1830318

次世代定序市場（按技術、產品類型、工作流程、最終用戶和應用）—全球預測 2025-2032

Next Generation Sequencing Market by Technology, Product Type, Workflow, End User, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，次世代定序市場將成長至 1,257.8 億美元，複合年成長率為 24.79%。

主要市場統計數據
基準年2024年 213.8億美元
預計2025年 266.9億美元
預測年份：2032年 1257.8億美元
複合年成長率（%） 24.79%

次世代定序的策略方向將技術進步和臨床應用與營運重點和相關人員的決策連結起來

次世代定序(NGS) 已從一項利基實驗室技術轉變為一個塑造生物醫學研究、診斷和生物製藥創新的基礎平台。本介紹概述了技術成熟度、不斷擴展的臨床應用以及決策者為有效利用 NGS 所必須應對的營運挑戰。定序化學、儀器通量和生物資訊學工具集的進步降低了技術門檻，同時在腫瘤學、感染疾病監測和罕見疾病遺傳學領域的實際部署也已證明其臨床效用。同時，隨著定序數據擴大為患者護理和治療發展提供資訊，企業對數據品質、互通性和法規遵從性的期望也日益提高。

要了解當前的情況，需要考察不斷發展的技術與使用者需求之間的相互作用。研究實驗室需要可重複的工作流程，以平衡吞吐量和準確性；臨床醫生需要可整合到電子健康記錄系統中的可操作報告；治療藥物開發人員則依賴高保真基因組數據進行生物標記發現和患者分層。因此，數據儲存、可擴展計算和強大的分析流程等基礎設施考量正變得與儀器選擇同等重要。隨著應用的推進，策略性相關人員不僅必須評估短期績效指標，還必須評估長期營運成本、供應商藍圖和生態系統夥伴關係。

本摘要強調 NGS 現在是一項系統級投資，為以下章節奠定了基礎：有效實施取決於將技術能力與工作流程要求和以患者為中心的結果相結合，同時適應不斷變化的監管期望和全球供應鏈動態。

技術、分析和監管趨勢的融合正在重新定義定序能力、驗證期望和協作部署模型

次世代定序領域正經歷一場變革性的轉變，這股變革由多元力量共同推動，再形成定序能力與應用。首先，儀器創新持續優先考慮速度、準確性和成本效益，從而實現了諸如快速感染疾病病原體鑑定和即時腫瘤檢驗等新用例。其次，生物資訊學正從客製化腳本轉向日益標準化和驗證的流程，其中包含比對、註釋和可重複的變異調用，可用於臨床報告。這些方法上的進步正在減少實驗室間的差異，並加快獲得結果的時間，從而擴大NGS的臨床和商業性價值提案。

同時，資料管理和儲存模式也在不斷發展。相關人員擴大採用將雲端儲存與本地運算相結合的混合架構，以平衡資料主權、延遲和安全性問題。與電子健康記錄和臨床決策支援工具的整合變得更加無縫，使基因組學見解能夠為照護現場決策提供資訊。法律規範正在適應這一現實，更加重視分析和臨床檢驗、將軟體視為醫療設備以及參考資料集的來源。最後，學術中心、診斷實驗室和生物製藥公司之間的夥伴關係正在加速檢測和伴隨診斷的共同開發，從而改變共同開發模式。這些轉變共同創造了一個動態環境，其中技術創新、驗證嚴謹性和生態系統夥伴關係共同決定了 NGS 的採用速度和範圍。

2025 年關稅如何改變定序供應鏈、採購行為以及實驗室和服務供應商的業務恢復策略

2025年美國加徵關稅，對次世代定序供應鏈、籌資策略和成本管理實務產生了多方面的影響，但並未改變基因組技術的基本科學價值。關稅影響了設備、試劑和輔助零件的流通，增加了進口到岸成本，並促使各組織重新評估供應商多元化。因此，採購團隊加快了區域供應商的資格認證流程，並尋求長期合約以穩定價格和供應承諾。同時，製造商和經銷商調整了庫存策略，維持更高的緩衝庫存，並調整了生產佈局，以降低關稅相關的中斷風險​​。

在營運方面，實驗室和服務供應商透過最佳化試劑利用率、整合訂單和協商配套服務協議來吸收關稅導致的成本增加。優先考慮臨床連續性的機構將重點轉移到有效的在地採購和加強服務等級協議，以確保設備執行時間。此外，關稅環境促使重新評估資本配置時間表。機構權衡了購買新的高通量測序儀的好處與增加的進口成本和潛在的延誤。同時，法規遵循和品管要求仍然是不可協商的，促使對工作流程效率進行投資，以便在採購動態發生動態時仍能維持分析績效。簡而言之，2025 年關稅的累積效應加速了供應鏈彈性規劃，並強調了綜合籌資策略和營運策略對於維持定序計畫的重要性。

綜合細分分析，協調技術類型、產品類型、工作流程階段、最終用戶配置文件和應用主導的優先級，以指導策略投資

關鍵細分洞察揭示了技術優勢和工作流程需求的交匯點，從而決定了實施和能力的優先順序。按技術分類，定序技術包括擴增子定序、基因面板定序、RNA定序、標靶定序、全EXOME子定序 (WES) 和全基因組定序 (WGS)，每種技術在深度、廣度和臨床效用都達到了不同的平衡，為平台和檢測方法的選擇提供參考。根據產品類型，產品分為消耗性試劑、儀器和軟體服務。消耗性試劑主要包括酵素和套件，儀器包括輔助設備和定序儀，軟體服務則分為資料分析軟體和服務，這反映了檢驗分析和可控解讀日益成長的重要性。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 整合單細胞多體學和空間轉錄組學以實現精準腫瘤學
  • 拓展長讀長定定序在結構變異分析與診斷的應用
  • 採用即時奈米孔定序進行現場感染疾病監測與控制
  • 引進自動化NGS文庫製備系統，減少週轉時間與錯誤
  • 人工智慧和機器學習平台的發展加速了NGS數據的分析和解釋
  • 直接RNA定序方法的出現提高了轉錄組分析的準確性和通量
  • 液態生物檢體NGS檢測在早期癌症檢測和微量殘存疾病監測的應用日益廣泛
  • 整合雲端原生生物資訊學流程，實現可擴展且安全的 NGS 資料管理工作流程
  • 擴大基於NGS的腫瘤伴隨診斷的監管核准和報銷途徑
  • 開發合成長讀技術來闡明複雜的基因組區域和單倍型定相

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章次世代定序市場（依技術）

  • 定序子定序
  • 基因組定序
  • RNA定序
  • 標靶定序
  • 全EXOME定序（WES）
  • 全基因測序（WGS）

第9章次世代定序市場（依產品類型）

  • 耗材試劑
    • 酵素
    • 套件
  • 裝置
    • 輔助設備
    • 序列器
  • 軟體服務
    • 數據分析軟體
    • 服務

第 10 章次世代定序市場（依工作流程）

  • 數據分析
    • 結盟
    • 評論
    • 變異調用
  • 資料儲存
    • 雲端儲存
    • 本地儲存
  • 樣品製備
    • 文庫製備
    • 準備模板
  • 定序

第 11 章次世代定序市場（依最終用戶）

  • 學術研究機構
  • 醫療保健診斷實驗室
  • 製藥和生物技術公司

第12章次世代定序市場（按應用）

  • 農業基因組學
  • 攜帶者篩檢
  • 表觀基因
  • 法醫學基因組學
  • 遺傳和罕見疾病
  • 感染疾病
  • 神經基因組學
  • 腫瘤學
  • 藥物基因組學

第13章次世代定序市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 14 章次世代定序市場：按類別

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國次世代定序市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Illumina, Inc.
    • Thermo Fisher Scientific Inc.
    • Roche Holding AG
    • QIAGEN NV
    • bioMerieux SA
    • Merck KGaA
    • Oxford Nanopore Technologies Ltd.
    • Agilent Technologies, Inc.
    • Danaher Corporation
    • F. Hoffmann-La Roche Ltd.
Product Code: MRR-4312A385A68A

The Next Generation Sequencing Market is projected to grow by USD 125.78 billion at a CAGR of 24.79% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 21.38 billion
Estimated Year [2025] USD 26.69 billion
Forecast Year [2032] USD 125.78 billion
CAGR (%) 24.79%

A strategic orientation to next generation sequencing that ties technological advances and clinical adoption to operational priorities and stakeholder decision-making

Next generation sequencing (NGS) has transitioned from a niche laboratory technique to a foundational platform shaping biomedical research, diagnostics, and biopharmaceutical innovation. This introduction outlines the technological maturation, broadening clinical applications, and operational challenges that decision-makers must reconcile to harness NGS effectively. Advances in sequencing chemistry, instrument throughput, and bioinformatic toolsets have lowered technical barriers, while real-world deployments in oncology, infectious disease surveillance, and rare disease genetics demonstrate tangible clinical utility. At the same time, organizations face rising expectations for data quality, interoperability, and regulatory compliance as sequencing data increasingly informs patient care and therapeutic development.

Understanding the current landscape requires attention to the interplay between technology evolution and user needs. Laboratories seek reproducible workflows that balance throughput with accuracy, clinicians demand actionable reports that integrate into electronic health record systems, and developers of therapeutics rely on high-fidelity genomic data for biomarker discovery and patient stratification. Consequently, infrastructure considerations such as data storage, scalable compute, and robust analysis pipelines have become as important as instrument selection. As adoption deepens, strategic stakeholders must evaluate not only immediate performance metrics but also long-term operational costs, vendor roadmaps, and ecosystem partnerships.

This summary sets the scene for subsequent sections by emphasizing that NGS is now a systems-level investment. Effective deployment hinges on aligning technical capabilities with workflow requirements and patient-centric outcomes, while adapting to evolving regulatory expectations and global supply chain dynamics.

Converging technological, analytical, and regulatory trends that are redefining sequencing capabilities, validation expectations, and collaborative deployment models

The landscape of next generation sequencing is undergoing transformative shifts driven by multiple converging forces that reshape both capability and adoption. First, instrument innovation continues to prioritize speed, accuracy, and cost-efficiency, enabling new use cases such as rapid infectious disease pathogen identification and real-time oncology monitoring. Second, bioinformatics has shifted from bespoke scripts to increasingly standardized, validated pipelines that incorporate alignment, annotation, and variant calling with reproducible outputs suitable for clinical reporting. These methodological advances reduce variability between laboratories and accelerate time-to-result, which in turn amplifies the clinical and commercial value proposition of NGS.

Concurrently, data management and storage paradigms have evolved; stakeholders increasingly adopt hybrid architectures that combine cloud storage with on-premise compute to reconcile data sovereignty, latency, and security concerns. Integration with electronic health records and clinical decision support tools is becoming more seamless, enabling genomic insights to inform point-of-care decisions. Regulatory frameworks are adapting to this reality, with a stronger focus on analytical and clinical validation, software-as-a-medical-device considerations, and the provenance of reference data sets. Finally, collaboration models are shifting as partnerships between academic centers, diagnostic labs, and biopharma accelerate co-development of assays and companion diagnostics. Together, these shifts create a dynamic environment where technical innovation, validation rigor, and ecosystem partnerships jointly determine the rate and scope of NGS adoption.

How 2025 tariff measures reshaped sequencing supply chains, procurement behaviors, and operational resilience strategies across laboratories and service providers

The introduction of tariffs by the United States in 2025 has exerted a multifaceted influence on next generation sequencing supply chains, procurement strategies, and cost-management practices without altering the underlying scientific value of genomic technologies. Tariff measures affected the flow of instruments, reagents, and ancillary components by increasing landed costs for imported items and prompting organizations to re-evaluate supplier diversification. As a result, procurement teams accelerated vendor qualification processes for regional suppliers and sought longer-term contracts to stabilize pricing and supply commitments. In parallel, manufacturers and distributors adjusted inventory strategies, maintaining higher buffer stocks and revisiting manufacturing footprints to mitigate the risk of tariff-related disruptions.

Operationally, laboratories and service providers adapted by optimizing reagent utilization, consolidating orders, and negotiating bundled service agreements that absorb some tariff-driven cost pressures. For institutions prioritizing clinical continuity, the emphasis shifted toward validated local sourcing and strengthened service-level agreements to ensure instrument uptime. Furthermore, the tariff environment prompted a reassessment of capital allocation timelines: organizations weighed the benefits of acquiring new high-throughput sequencers against incremental import costs and potential delays. At the same time, regulatory compliance and quality control requirements remained non-negotiable, driving investments in workflow efficiencies that preserve analytical performance even as procurement dynamics change. In essence, the cumulative effect of tariffs in 2025 accelerated supply-chain resilience planning and reinforced the importance of integrated procurement and operational strategies to sustain sequencing programs.

Integrated segmentation analysis that aligns technology types, product categories, workflow stages, end-user profiles, and application-driven priorities to guide strategic investment

Key segmentation insights reveal where technological strengths and workflow demands intersect to shape adoption and capability priorities. Based on Technology, the landscape spans Amplicon Sequencing, Gene Panel Sequencing, RNA Sequencing, Targeted Sequencing, Whole Exome Sequencing (WES), and Whole Genome Sequencing (WGS), each offering a distinct balance of depth, breadth, and clinical utility that informs platform and assay selection. Based on Product Type, offerings are organized across Consumables Reagents, Instruments, and Software Services; within Consumables Reagents the focus narrows to Enzymes and Kits, while Instruments distinguish Ancillary Instruments from Sequencers, and Software Services break down into Data Analysis Software and Services, reflecting the rising importance of validated analytics and managed interpretation.

Based on Workflow, critical stages include Data Analysis, Data Storage, Sample Preparation, and Sequencing; Data Analysis further segments into Alignment, Annotation, and Variant Calling, Data Storage differentiates Cloud Storage from On-Premise Storage, and Sample Preparation separates Library Preparation from Template Preparation, underscoring that bottlenecks can occur at multiple touchpoints beyond the sequencer itself. Based on End User, adoption patterns differ among Academic Research Institutes, Healthcare Diagnostic Laboratories, and Pharmaceutical Biotechnology Companies, each of which prioritizes different performance metrics, regulatory rigor, and scale considerations. Based on Application, deployments range across Agrigenomics, Carrier screening, Epigenomics, Forensic Genomics, Genetic & Rare Diseases, Infectious Diseases, Neurogenomics, Oncology, and Pharmacogenomics, demonstrating that application-specific requirements drive assay design, data interpretation needs, and downstream clinical or commercial pathways.

Taken together, these segmentation lenses show that strategic investments should align technology choice with specific workflow pinch points and end-user requirements, while emphasizing interoperable analysis and storage solutions that accommodate diverse applications and validation needs.

Regional deployment dynamics that influence sequencing adoption, regulatory alignment, and infrastructure investments across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics continue to shape how next generation sequencing capabilities roll out and scale across different health systems, research networks, and commercial ecosystems. In the Americas, deployment trends emphasize clinical diagnostics, oncology applications, and a robust diagnostics services market supported by advanced bioinformatics providers and cloud-native storage solutions. North American academic centers and biotech hubs drive method validation and translational research, while commercial lab networks focus on assay standardization and high-throughput workflows.

In Europe, Middle East & Africa, regulatory harmonization, data protection frameworks, and diverse healthcare reimbursement models influence adoption cadence. European research consortia and national public health initiatives frequently collaborate to establish reference standards, while regional manufacturers and service providers respond to varying data sovereignty requirements by offering localized storage and compute options. Emerging hubs in the Middle East and North Africa are investing in sequencing capacity for public health surveillance and precision medicine pilot programs.

Across Asia-Pacific, growth patterns reflect a mix of government-led sequencing initiatives, expansive clinical sequencing adoption in select markets, and strong manufacturing capabilities for instruments and reagents. Several countries prioritize genomics for population health, infectious disease surveillance, and agriculture, prompting significant investments in laboratory infrastructure and workforce training. In each region, the balance of public and private funding, regulatory pathways, and local academic-industry collaborations determines how sequencing technologies are integrated into broader healthcare and research agendas.

Competitive ecosystem analysis revealing how instrument makers, reagent suppliers, analytics vendors, and service laboratories converge to offer integrated sequencing value propositions

Competitive positioning in the sequencing ecosystem reflects a blend of instrument manufacturers, reagent suppliers, software and analytics providers, and service laboratories, each pursuing distinct value propositions. Leading instrument providers concentrate on throughput, accuracy, and integrated workflow solutions, while reagent and kit suppliers emphasize reliability, lot-to-lot consistency, and regulatory-ready documentation to meet clinical validation needs. Software and services vendors differentiate through validated analysis pipelines, interpretive content, and managed services that reduce the interpretive burden on laboratories and clinicians.

Service laboratories and contract research organizations play a complementary role by offering scalable sequencing capacity, assay development partnerships, and decentralized testing models that allow clinical and research customers to access advanced capabilities without immediate capital investment. Strategic partnerships and licensing deals increasingly blur traditional vendor boundaries, as companies combine hardware, consumables, and analytic services into cohesive offerings that accelerate end-to-end validation. In response, purchasers evaluate vendors not only on instrument specifications but also on ecosystem support, data portability, and long-term roadmap commitments that ensure compatibility with evolving clinical standards and bioinformatic requirements.

Practical strategic guidance for leaders to align technology selection, data infrastructure, supply resilience, and partnership models to scale sequencing responsibly

Actionable recommendations for industry leaders focus on aligning technology selection, operational design, and partnership strategies to capture the full potential of sequencing while managing risks related to validation, supply chain, and data governance. First, prioritize modular and validated workflows that allow incremental scaling; selecting platforms and consumables that interoperate with standardized analysis pipelines reduces time-to-clinical-readiness and simplifies regulatory pathways. Second, invest in hybrid data architectures that balance cloud scalability with on-premise control to meet data sovereignty requirements and latency-sensitive clinical use cases. Third, develop supplier diversity strategies and longer-term procurement agreements that address tariff and supply disruption risks while preserving quality and documentation standards required for clinical use.

Additionally, cultivate strategic partnerships that extend beyond transactional procurement: co-development agreements with assay developers, data-sharing partnerships with academic centers, and managed service arrangements with analytics providers accelerate validation and broaden access. Upskilling laboratory staff in bioinformatics and quality systems is essential to maintain analytical rigor as workflows scale, and embedding interpretive expertise into clinical reports will improve clinician confidence and patient outcomes. Finally, regularly assess regulatory trajectories and engage with standards-setting bodies to ensure that internal validation programs and software development practices remain aligned with emerging guidance. These steps together create a resilient, scalable pathway from laboratory innovation to routine clinical impact.

A triangulated research methodology combining primary stakeholder interviews, laboratory workflow benchmarking, and secondary validation to produce robust sequencing insights

The research methodology underpinning this report synthesizes primary stakeholder interviews, laboratory workflow analyses, and rigorous secondary-source validation to ensure evidence-based conclusions. Primary inputs included consultations with instrument engineers, clinical laboratory directors, bioinformatics leaders, and procurement specialists to capture real-world constraints and innovation priorities. These qualitative engagements were complemented by structured workflow observations and technical benchmark assessments that focused on sequencing accuracy, time-to-result, and integration challenges across sample preparation, sequencing, and analysis stages.

Secondary validation incorporated peer-reviewed literature, regulatory guidance documents, and technology white papers to corroborate trends identified in primary research and to contextualize developments in bioinformatics and data management. Where applicable, comparative assessments of analytical pipelines-covering alignment, annotation, and variant calling-were performed to highlight reproducibility considerations and interpretive bottlenecks. The methodology emphasizes triangulation across data sources, transparency in assumptions, and clarity about the limits of inference, ensuring that findings are both actionable and grounded in a robust evidence base. Throughout, the approach maintained strict attention to data integrity, reproducibility, and the practical needs of laboratory and clinical stakeholders.

Concluding synthesis emphasizing that validated workflows, resilient operations, and collaborative execution unlock the full clinical and research value of sequencing technologies

This executive summary synthesizes the strategic realities of next generation sequencing: technological advances have expanded application breadth and clinical relevance, while operational complexities related to workflows, data, and procurement determine effective adoption. Stakeholders must approach sequencing as a systems challenge that spans instrument selection, validated consumables, interoperable analytics, and resilient supply chains. Emerging regulatory emphasis on validation and software integrity increases the premium on reproducible pipelines and documented quality management systems, and tariff-related procurement dynamics highlight the necessity of diversified sourcing and strategic vendor relationships.

Looking forward, the most successful organizations will combine technical excellence with operational foresight-investing in hybrid data infrastructures, workforce upskilling, and collaborative partnerships that accelerate validation and clinical integration. By focusing on validated workflows, robust data governance, and adaptive procurement strategies, leaders can translate sequencing capabilities into measurable research and clinical value. This conclusion underscores that the promise of genomic technologies will be realized not solely through isolated innovations, but through disciplined execution across the full sequencing ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of single-cell multiomics and spatial transcriptomics for precision oncology
  • 5.2. Expansion of long-read sequencing applications in structural variant analysis and diagnostics
  • 5.3. Adoption of real-time nanopore sequencing for on-site infectious disease surveillance and control
  • 5.4. Implementation of automated NGS library preparation systems to reduce turnaround times and errors
  • 5.5. Growth of AI and machine learning platforms for accelerated NGS data analysis and interpretation
  • 5.6. Emergence of direct RNA sequencing methods to improve transcriptome profiling accuracy and throughput
  • 5.7. Rising adoption of liquid biopsy NGS assays for early cancer detection and minimal residual disease monitoring
  • 5.8. Integration of cloud-native bioinformatics pipelines for scalable and secure NGS data management workflows
  • 5.9. Expansion of regulatory approvals and reimbursement pathways for NGS-based companion diagnostics in oncology
  • 5.10. Development of synthetic long-read technologies to resolve complex genomic regions and haplotype phasing

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Next Generation Sequencing Market, by Technology

  • 8.1. Amplicon Sequencing
  • 8.2. Gene Panel Sequencing
  • 8.3. RNA Sequencing
  • 8.4. Targeted Sequencing
  • 8.5. Whole Exome Sequencing (WES)
  • 8.6. Whole Genome Sequencing (WGS)

9. Next Generation Sequencing Market, by Product Type

  • 9.1. Consumables Reagents
    • 9.1.1. Enzymes
    • 9.1.2. Kits
  • 9.2. Instruments
    • 9.2.1. Ancillary Instruments
    • 9.2.2. Sequencers
  • 9.3. Software Services
    • 9.3.1. Data Analysis Software
    • 9.3.2. Services

10. Next Generation Sequencing Market, by Workflow

  • 10.1. Data Analysis
    • 10.1.1. Alignment
    • 10.1.2. Annotation
    • 10.1.3. Variant Calling
  • 10.2. Data Storage
    • 10.2.1. Cloud Storage
    • 10.2.2. On-Premise Storage
  • 10.3. Sample Preparation
    • 10.3.1. Library Preparation
    • 10.3.2. Template Preparation
  • 10.4. Sequencing

11. Next Generation Sequencing Market, by End User

  • 11.1. Academic Research Institutes
  • 11.2. Healthcare Diagnostic Laboratories
  • 11.3. Pharmaceutical Biotechnology Companies

12. Next Generation Sequencing Market, by Application

  • 12.1. Agrigenomics
  • 12.2. Carrier screening
  • 12.3. Epigenomics
  • 12.4. Forensic Genomics
  • 12.5. Genetic & Rare Diseases
  • 12.6. Infectious Diseases
  • 12.7. Neurogenomics
  • 12.8. Oncology
  • 12.9. Pharmacogenomics

13. Next Generation Sequencing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Next Generation Sequencing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Next Generation Sequencing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Illumina, Inc.
    • 16.3.2. Thermo Fisher Scientific Inc.
    • 16.3.3. Roche Holding AG
    • 16.3.4. QIAGEN N.V.
    • 16.3.5. bioMerieux S.A.
    • 16.3.6. Merck KGaA
    • 16.3.7. Oxford Nanopore Technologies Ltd.
    • 16.3.8. Agilent Technologies, Inc.
    • 16.3.9. Danaher Corporation
    • 16.3.10. F. Hoffmann-La Roche Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NEXT GENERATION SEQUENCING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. NEXT GENERATION SEQUENCING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NEXT GENERATION SEQUENCING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GENE PANEL SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GENE PANEL SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GENE PANEL SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GENE PANEL SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GENE PANEL SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GENE PANEL SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY RNA SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY RNA SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY RNA SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY RNA SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY RNA SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY RNA SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WHOLE EXOME SEQUENCING (WES), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WHOLE EXOME SEQUENCING (WES), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WHOLE EXOME SEQUENCING (WES), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WHOLE EXOME SEQUENCING (WES), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WHOLE EXOME SEQUENCING (WES), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WHOLE EXOME SEQUENCING (WES), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WHOLE GENOME SEQUENCING (WGS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WHOLE GENOME SEQUENCING (WGS), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WHOLE GENOME SEQUENCING (WGS), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WHOLE GENOME SEQUENCING (WGS), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WHOLE GENOME SEQUENCING (WGS), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WHOLE GENOME SEQUENCING (WGS), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ENZYMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ENZYMES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ENZYMES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ENZYMES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ANCILLARY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ANCILLARY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ANCILLARY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ANCILLARY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ANCILLARY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ANCILLARY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SEQUENCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SEQUENCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SEQUENCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SEQUENCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ALIGNMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ALIGNMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ALIGNMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ALIGNMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ALIGNMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ALIGNMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ANNOTATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ANNOTATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ANNOTATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ANNOTATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ANNOTATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ANNOTATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY VARIANT CALLING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY VARIANT CALLING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY VARIANT CALLING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY VARIANT CALLING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY VARIANT CALLING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY VARIANT CALLING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CLOUD STORAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CLOUD STORAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CLOUD STORAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CLOUD STORAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CLOUD STORAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CLOUD STORAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ON-PREMISE STORAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ON-PREMISE STORAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ON-PREMISE STORAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ON-PREMISE STORAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ON-PREMISE STORAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ON-PREMISE STORAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TEMPLATE PREPARATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TEMPLATE PREPARATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TEMPLATE PREPARATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TEMPLATE PREPARATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TEMPLATE PREPARATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY TEMPLATE PREPARATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY HEALTHCARE DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY HEALTHCARE DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY HEALTHCARE DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY HEALTHCARE DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY HEALTHCARE DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY HEALTHCARE DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY AGRIGENOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY AGRIGENOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY AGRIGENOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY AGRIGENOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY AGRIGENOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY AGRIGENOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CARRIER SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CARRIER SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CARRIER SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY CARRIER SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY EPIGENOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY EPIGENOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY EPIGENOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY EPIGENOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY EPIGENOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY EPIGENOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY FORENSIC GENOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY FORENSIC GENOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY FORENSIC GENOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY FORENSIC GENOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY FORENSIC GENOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY FORENSIC GENOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GENETIC & RARE DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GENETIC & RARE DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GENETIC & RARE DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GENETIC & RARE DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GENETIC & RARE DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GENETIC & RARE DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY NEUROGENOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY NEUROGENOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY NEUROGENOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY NEUROGENOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY NEUROGENOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY NEUROGENOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA STORAGE, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS NEXT GENERATION SEQUENCING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY CONSUMABLES REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY SOFTWARE SERVICES, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY WORKFLOW, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA NEXT GENERATION SEQUENCING MARKET SIZE, BY DATA ANALYSIS